Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

1.330 -0.060 (-4.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coherus Bio

< Previous 1 2 3 Next >
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
From Coherus BioSciences, Inc.
Via GlobeNewswire
FDA Approves UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Present at Upcoming Investor Conferences in March
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Junshi Biosciences
Via GlobeNewswire
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical
From Coherus BioSciences, Inc.; Shanghai Junshi Biosciences Co., Ltd
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.